Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
June 2012, Vol 3, No 4
June 2012, Vol 3, No 4
Biomarker Identifies Patients with Rare Brain Tumors Who Have a Survival Benefit from Chemotherapy Plus Radiation
By
Phoebe Starr
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Patients with the relatively rare brain tumor anaplastic oligodendroglioma who were treated with adjuvant chemotherapy after standard radiation therapy had improved survival compared with radiation alone, especially if they had codeletion of chromosomes 1p/19q, according to long-term follow-up of the EORTC (European Organisation for Research and Treatment of Cancer) 2651 study reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Read Article
Late-Breaking Clinical Trials: Potential New Therapies for Lymphoma, Prostate, and Other Cancers
AACR Annual Meeting
June 2012, Vol 3, No 4
Chicago, IL—Several presentations featured at a news conference at the 2012 American Association for Cancer Research meeting highlighted new therapies showing promising results in the early stage of research, potentially charting new options for patients with cancer.
Read Article
Brain, Breast, and Liver Cancers All Respond to Immunotherapy
By
Richard Hyer
AACR Annual Meeting
June 2012, Vol 3, No 4
There is progress in at least 4 areas: pediatric brain tumors, breast cancer, hepatocellular carcinoma, and generally advanced cancers, according to 4 current studies described at the 2012 American Association for Cancer Research meeting.
Read Article
Ipilimumab-GVAX Combination Safe for Metastatic Castration-Resistant Prostate Cancer
In the Literature
June 2012, Vol 3, No 4
A combination of ipilimumab and the granulocyte-macrophage colonystimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) was feasible and tolerable in an openlabel phase 1 study in men with metastatic castration-resistant prostate cancer (van den Eertwegh AJM, et al.
Lancet Oncol
. 2012;13:509-517).
Read Article
Navitoclax Shows Limited Clinical Activity in SCLC, but Findings Point to Potential New Biomarkers
In the Literature
June 2012, Vol 3, No 4
When oral navitoclax (ABT-263) was evaluated in an open-label, phase 2 study in adult patients with recurrent and progressive small-cell lung cancer (SCLC) who had received at least 1 prior therapy, this Bcl-2 inhibitor showed only limited activity (Rudin CM, et al.
Clin Cancer Res
. 2012;18;1-7).
Read Article
Radiation Breakdown: All That Glitters Is Not Gold
By
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Baltimore, MD—Radiation technologies rank as some of the most interesting new developments. However, the advantages of these new technologies in terms of patient outcomes are sometimes elusive, and the costs of acquiring radiologic facilities—and the revenue generated by them—are increasingly coming into question.
Read Article
More Revenue, Less Waste: Tips for Optimizing Financial Performance
By
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
At the 2012 Association of Community Cancer Centers meeting, several presenters offered practical tips to help in the new climate of healthcare reform.
Read Article
Integrating Digital Patient Engagement into Your Care Model
By
Gena Cook
Practice Management
,
Value Peer-spectives
June 2012, Vol 3, No 4
The Health Information Technology for Economic and Clinical Health (HITECH) Act has set aside $19 billion in incentives to encourage healthcare providers to adopt and meaningfully use electronic medical record (EMR) technology in an effort to provide more patient-centered care.
Read Article
CareFirst Oncology Management Program Aims to Manage the “Entire Oncology Patient”
By
Caroline Helwick
June 2012, Vol 3, No 4
The Oncology Management Program at CareFirst Blue Cross Blue Shield (BCBS) continues to evolve, producing nearly 10% in cost-savings over prepathways practice, and ensuring that patients get more appropriate care, said Winston Wong, PharmD, Associate Vice President of Pharmacy Management at CareFirst BCBS, who described the program at the Second Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Personalized Medicine Empowers Treatment Decisions
By
Caroline Helwick
June 2012, Vol 3, No 4
Houston, TX—“Personalized medicine can improve healthcare delivery, improve healthcare outcomes, and help manage healthcare costs and spending,” said Jeffrey Scott, MD, Senior Vice President, General Manager for P4 Healthcare/Cardinal Health Specialty Solutions, at the Second Annual Con ference of the Association for Value-Based Cancer Care.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma